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Using both confocal immunofluorescence microscopy and bio-
chemical approaches, we have examined the role of b-arrestins
in the activation and targeting of extracellular signal-regulated
kinase 2 (ERK2) following stimulation of angiotensin II type 1a
receptors (AT1aR). In HEK-293 cells expressing hemagglutinin-
tagged AT1aR, angiotensin stimulation triggered b-arrestin-2
binding to the receptor and internalization of AT1aR-b-arrestin
complexes. Using red fluorescent protein-tagged ERK2 to track
the subcellular distribution of ERK2, we found that angiotensin
treatment caused the redistribution of activated ERK2 into
endosomal vesicles that also contained AT1aR-b-arrestin com-
plexes. This targeting of ERK2 reflects the formation of multi-
protein complexes containing AT1aR, b-arrestin-2, and the com-
ponent kinases of the ERK cascade, cRaf-1, MEK1, and ERK2.
Myc-tagged cRaf-1, MEK1, and green fluorescent protein-tagged
ERK2 coprecipitated with Flag-tagged b-arrestin-2 from trans-
fected COS-7 cells. Coprecipitation of cRaf-1 with b-arrestin-2
was independent of MEK1 and ERK2, whereas the coprecipita-
tion of MEK1 and ERK2 with b-arrestin-2 was significantly
enhanced in the presence of overexpressed cRaf-1, suggesting
that binding of cRaf-1 to b-arrestin facilitates the assembly of a
cRaf-1, MEK1, ERK2 complex. The phosphorylation of ERK2 in
b-arrestin complexes was markedly enhanced by coexpression
of cRaf-1, and this effect is blocked by expression of a catalyt-
ically inactive dominant inhibitory mutant of MEK1. Stimulation
with angiotensin increased the binding of both cRaf-1 and ERK2
to b-arrestin-2, and the association of b-arrestin-2, cRaf-1, and
ERK2 with AT1aR. These data suggest that b-arrestins function
both as scaffolds to enhance cRaf-1 and MEK-dependent acti-
vation of ERK2, and as targeting proteins that direct activated
ERK to specific subcellular locations.
The traditional model of G protein-coupled receptor functionis that signals emanating from these heptahelical receptors
arise from their ability to catalyze the activation of heterotri-
meric G proteins, whose dissociated subunits interact with
enzymatic effectors, such as adenylyl cyclases, phospholipases,
and ion channels, to regulate intermediary metabolism (1). Over
the past decade, it has become clear that these receptors
additionally function as important regulators of cell proliferation
and differentiation in a variety of physiologic and pathophysio-
logic settings (2). In many cases, these effects correlate with the
ability of heptahelical receptors to stimulate mitogen-activated
protein kinase (MAPK) cascades.
Efforts to understand how these receptors regulate MAPK
activity have led to the discovery of several previously unappre-
ciated mechanisms of heptahelical receptor signaling (3, 4).
Among these is the finding that, in addition to their originally
described role of uncoupling agonist-occupied, G protein-
coupled receptor kinase (GRK) phosphorylated receptors from
their cognate G proteins (5), b-arrestins can function as adapter
proteins that promote the stable association of signaling proteins
with the heptahelical receptor. By binding to both the nonre-
ceptor tyrosine kinase, c-Src, and to agonist-occupied b2 adren-
ergic receptors, b-arrestin-1 can confer tyrosine kinase activity
upon the receptor (6, 7). Similarly, b-arrestins are involved in
recruiting c-Src to the Neurokinin-1 receptor in KNRK kidney
epithelial cells (8) and recruiting the Src family kinases, Hck and
c-Fgr, to the CXCR-1 receptor in neutrophils (9). In addition,
recent reports have indicated that b-arrestins can interact di-
rectly with component kinases of the extracellular signal-
regulated kinase (ERK) and c-Jun N-terminal kinase (JNK)
MAPK cascades. b-Arrestins form complexes with internalized
protease-activated receptor 2 (PAR-2), Raf-1 and ERK1y2 (10),
and with internalized neurokinin-1 receptor, c-Src and ERK1y2
(8). b-Arrestin-2 also acts as a scaffold for the component
kinases of the JNK3 cascade, facilitating JNK3 activation by
binding directly to JNK3 and the MAPK kinase kinase, Ask1
(11). The formation of stable complexes between a heptahelical
receptor, b-arrestin, and a MAPK may also affect substrate
specificity by constraining the spatial distribution of the activated
MAPK.
We have studied the role of b-arrestins in the activation and
targeting of ERK2 by angiotensin II type 1a receptors (AT1aR).
Confocal immunofluorescence microscopy was used to track the
spatial redistribution of AT1aR, b-arrestin-2, and ERK2 follow-
ing angiotensin stimulation in HEK-293 cells. Transiently trans-
fected COS-7 cells were used to assay the interaction of AT1aR,
b-arrestin-2, and the component kinases of the ERK2 cascade,
and to determine the role of b-arrestin-2 in ERK2 activation. We
find that the formation of complexes between ATa1R, b-arres-
tin-2, and the component kinases of the ERK MAPK cascade
leads to the activation of b-arrestin-bound ERK2 and the
targeting of a pool of activated ERK2 into endosomal vesicles
containing the internalized AT1aR.
Materials and Methods
Materials. The pDsRed1-N1 plasmid was obtained from CLON-
TECH. FuGene 6 was from Roche Diagnostics, and Lipo-
fectAMINE was from GIBCOyBRL. Dithiobis[succinimidyl-
propionate] (DSP) was from Pierce. Monoclonal M2 anti-Flag
affinity agarose and FITC-conjugated monoclonal anti-
phospho-ERK1y2 were obtained from Sigma. Monoclonal
HA.11 anti-hemagglutinin (HA) affinity agarose was obtained
from Covance (Princeton, NJ). Rhodamine-conjugated mono-
clonal anti-HA antiserum was obtained from Molecular Probes.
Polyclonal anti-ERK1y2 and anti-phospho-ERK1y2 antisera
were from New England Biolabs. Rabbit polyclonal anti-Flag
antiserum and anti-cRaf-1 were from Santa Cruz Biotechnology,
and monoclonal anti-MEK1 was from Transduction Laborato-
ries (Lexington, KY). Horseradish peroxidase-conjugated poly-
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clonal donkey anti-rabbit and anti-mouse IgG were obtained
from Jackson ImmunoResearch.
DNA Constructs. pcDNA3.1 expression plasmids encoding HA-
tagged AT1aR (12), and green fluorescent protein (GFP)-
tagged b-arrestin-2 (13) were provided by L. Barak, R. Oakley,
and M. G. Caron (Duke University). The pEGFP-N1 expression
plasmid encoding GFP-tagged ERK2 (10) was provided by K.
DeFea and N. Bunnett (University of California at San Fran-
cisco). The expression plasmid for red fluorescent protein
(RFP)-tagged ERK2 was created by subcloning a BamHI re-
striction fragment encoding ERK2 from the pEGFP-N1 ERK2
plasmid into the polylinker region of the pDsRed1-N1 plasmid.
Expression plasmids encoding cRaf-1 (14) and MEK-1 (15) were
provided by C. Der (University of North Carolina, Chapel Hill),
E. Krebs (University of Washington), and R. Seger (The Weitz-
mann Institute of Science). All other expression plasmids were
created in our laboratory as previously described (7, 11).
Cell Culture and Transfection. HEK-293 and COS-7 cells were from
the American Type Culture Collection. HEK-293 cells were
maintained in Minimum Essential Medium with Earle’s Salts
supplemented with 10% FBS and 1% penicillinystreptomycin at
37°C in a humidified 5% CO2 atmosphere. COS-7 cells were
maintained in DMEM supplemented with 10% FBS and 1%
penicillinystreptomycin. Transient transfection of HEK-293 cells
was performed by using FuGene 6 according to the manufac-
turer’s instructions. Transient transfection of COS-7 cells was
performed by using LipofectAMINE as previously described
(16). Monolayers of transfected cells were incubated in serum-
free growth medium supplemented with 10 mM Hepes, pH 7.4,
0.1% BSA, and 1% penicillinystreptomycin for 16–20 h before
stimulation. Agonist stimulations were performed at 37°C in
serum-free media as described in the figure legends.
Confocal Microscopy. HEK-293 cells were used for experiments
performed using confocal microscopy because of their favorable
morphology for simultaneously examining the cytoplasmic and
nuclear distribution of proteins. For visualization of HA-AT1aR,
transiently transfected HEK-293 cells in collagen-coated 35-mm
glass-bottom dishes were stained with a 1:500 dilution of rhodam-
ine-conjugated monoclonal anti-HA antiserum for 1 h at 37°C.
Cells were then stimulated as described in the figure legends,
washed with Dulbecco’s PBS, fixed with 10% paraformaldehyde for
30 min at room temperature, and again washed with PBS prior to
examination. For visualization of GFP-b-arrestin-2 and RFP-
ERK2, cells were stimulated and fixed with paraformaldehyde as
described. For visualization of phospho-ERK1y2, cells were stim-
ulated and fixed as described, permeabilized with absolute meth-
anol for 10 min at 220°C, and blocked with 1% BSAy5% FBS for
3 h at room temperature. Cells were then stained using a 1:100
dilution FITC-conjugated monoclonal anti-phospho-ERK1y2 in
1% BSAy1% FBS for 24 h at 4°C, and washed with PBS prior to
examination. Confocal microscopy was performed on a Zeiss
LSM510 laser scanning microscope using a Zeiss 63 3 1.4 numer-
ical aperture water immersion lens with dual line switching excita-
tion (488 nm for GFP, 568 nm for rhodamine) and emission
(515–540 nm GFP, 590–610 nm rhodamine) filter sets.
Immunoprecipitation and Protein Immunoblotting. Immunoprecipi-
tation experiments were performed by using transiently trans-
fected COS-7 cells in 100-mm dishes. Cells were stimulated as
described in the figure legends and solubilized in 1 ml of
immunoprecipitation buffer containing 250 mM NaCl, 50 mM
Hepes, 0.5% Nonidet P-40, 10% glycerol, 2 mM EDTA, 1 mM
sodium orthovanadate, 1 mM PMSF, 10 mgyml leupeptin, and 10
mgyml aprotinin. To detect AT1aR-associated proteins, stimu-
lated cells were subjected to covalent protein crosslinking by
using the membrane permeable hydrolyzable crosslinker, DSP,
as previously described (6). A 50-ml aliquot of each clarified
whole-cell lysate was mixed with an equal volume of 23 Laemmli
sample buffer and resolved by SDSyPAGE for confirmation of
plasmid expression by immunoblotting.
Immunoprecipitation of full-length and truncated Flag-b-
arrestin-2 was performed using monoclonal M2 anti-Flag affinity
agarose, as previously described (7). Immunoprecipitation of
HA-AT1aR was performed similarly, using monoclonal HA.11
anti-HA affinity agarose. Immunoprecipitates were resolved by
SDS-PAGE and transferred to poly(vinylidene difluoride) mem-
brane for immunoblotting. Protein immunoblotting for full-
length and truncated Flag-b-arrestin-2 was performed by using
rabbit polyclonal anti-FLAG antiserum. Coprecipitated cRaf-1,
MEK1, ERK2, and phospho-ERK2 were detected by using
polyclonal anti-cRaf-1, monoclonal anti-MEK1, and polyclonal
anti-ERK1y2 and anti-phospho-ERK1y2 antisera, respectively.
Horseradish peroxidase-conjugated polyclonal donkey anti-
rabbit and anti-mouse IgG were used as secondary antibody as
appropriate. Immune complexes on poly(vinylidene difluoride)
filters were visualized by enzyme-linked chemiluminescence and
quantified by scanning laser densitometry.
Results
Activated ERK Colocalizes with AT1aR-b-Arrestin Complexes Follow-
ing Angiotensin II Stimulation. The stimulation of AT1aR results in
the rapid recruitment of b-arrestins from the cytoplasm to the
agonist-occupied receptor on the plasma membrane, followed by
the trafficking of receptor-b-arrestin complexes into endosomal
vesicles (12). This formation of stable internalized AT1aR-b-
arrestin complexes is shown by confocal immunofluorescence
microscopy in Fig. 1A. In the absence of ligand, HA-AT1aR were
distributed along the plasma membrane (Top, red), whereas
GFP-b-arrestin-2 (Top, green) was diffusely cytosolic in distri-
bution. After 15 min of exposure to angiotensin II, receptor and
b-arrestin each underwent a dramatic redistribution, with both
proteins translocating to a common endosomal vesicle compart-
ment (Bottom, yellow; arrows).
To determine the effect of angiotensin stimulation on the cellular
distribution of ERKs, we used transiently expressed RFP-ERK2.
Expression of this chimera permitted simultaneous imaging of
RFP-ERK2 and GFP-b-arrestin-2. As shown in Fig. 1B, both
GFP-b-arrestin-2 (Top, green) and RFP-ERK2 (Top, red) are
diffusely cytosolic in nonstimulated cells. Treatment for 15 min with
phorbol myristate acetate (PMA), which causes rapid protein
kinase C-dependent activation of ERK1y2 (17), resulted in trans-
location of the RFP-ERK2 to the nucleus (Second row, red),
without affecting the cytosolic distribution of GFP-b-arrestin-2
(Second row, green). In contrast, stimulation of AT1aR caused a
distinctive redistribution of both proteins. After 15 min of agonist
treatment, the GFP-b-arrestin-2, as expected, was found predom-
inantly in endosomal vesicles (Third and Bottom rows, green;
arrows). Although some of the RFP-ERK2 redistributed to the
nucleus, a significant amount of the kinase colocalized with GFP-
b-arrestin-2 in vesicles (Third and Bottom rows, red; arrows).
Because these endosomal vesicles also contain the internalized
AT1aR (Fig. 1A), these data suggest that internalized b-arrestin-
bound AT1aRs can exist in complex with ERK2.
To determine the activation state of the RFP-ERK2 that colo-
calized with b-arrestin-2, cells coexpressing Flag-b-arrestin-2 and
RFP-ERK2 were stained with FITC-conjugated anti-phospho
ERK1y2 antiserum after stimulation. This antibody, which recog-
nizes Thr202yTyr204-phosphorylated ERK1y2, is specific for ac-
tivated ERK1y2 (18). As shown in Fig. 2, there was no significant
staining of cytosolic phospho-RFP-ERK2 in quiescent cells (Top).
Stimulation for 15 min with PMA resulted in a redistribution of
RFP-ERK2 from the cytoplasm to the nucleus (Second row, red)
and an increase in FITC-stained phospho-ERK in both the cyto-
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plasm and nucleus (Second row, green). Following angiotensin
stimulation, FITC-stained phospho-ERK appeared both in the
nucleus and in endosomal vesicles that colocalized with RFP-ERK2
(Third and Bottom rows; arrows). Thus, angiotensin stimulation
resulted in the targeting of a significant fraction of the activated
RFP-ERK2 to endosomal vesicles, resulting in a spatially con-
strained pool of activated ERK.
b-Arrestins Act as Scaffolds That Facilitate the Targeting and Raf-
Dependent Activation of ERKs. The data obtained by confocal
microscopy suggest that AT1aR, b-arrestin-2, and activated
ERK2 are targeted to endosomal vesicles following activation of
the receptor. To examine the structural basis for this phenom-
enon, we used COS-7 cells transiently overexpressing Flag-b-
arrestin-2 and each of the component kinases of the ERK
cascade singly and in combination. As shown in Fig. 3A, myc-
cRaf-1, MEK-1, and GFP-ERK2 were each detected in anti-Flag
immunoprecipitates when coexpressed with Flag-b-arrestin-2.
Simultaneous expression of either MEK1 or GFP-ERK2 had no
effect on the amount of myc-cRaf-1 that precipitated with
Flag-b-arrestin-2. Similarly, simultaneous expression of MEK1
and GFP-ERK2 did not affect the precipitation of either kinase
with Flag-b-arrestin-2. In contrast, coexpression of myc-cRaf-1
enhanced the precipitation of both MEK1 and GFP-tagged
ERK2 with Flag-b-arrestin-2. As shown in Fig. 3B, coexpression
of myc-cRaf-1 increased ERK2 binding to Flag-b-arrestin-2
approximately 3- to 4-fold, suggesting that the binding of ERK2
to b-arrestin-2 may be at least partially indirect. These data
Fig. 1. Effect of angiotensin II on the cellular distribution of HA-AT1aR, GFP-b-
arrestin-2, and RFP-ERK2. (a) HEK-293 cells were transiently transfected with
plasmid DNA encoding HA-AT1aR and GFP-b-arrestin-2. Serum-starved cells were
prestained with anti-HA rhodamine to label cell surface HA-AT1aR, treated with
vehicle (NS) or angiotensin II (Ang II, 1 mM) for 15 min, fixed with paraformalde-
hyde, and examined by confocal microscopy. The distribution of rhodamine-
labeled HA-AT1aR (red) and GFP-b-arrestin-2 (green) are shown in the single
channel images. Colocalization of HA-AT1aR and GFP-b-arrestin-2 is shown in the
overlay images (yellow; arrows). (b) Cells were transiently transfected with plas-
mid DNA encoding HA-AT1aR, GFP-b-arrestin-2, and RFP-ERK2. Serum-starved
cells were treated with vehicle (NS) or PMA (100 nM) or angiotensin II (Ang II) for
15min,andfixedcellswereexaminedbyconfocalmicroscopy.Thedistributionof
GFP-b-arrestin-2 (green) and RFP-ERK2 (red) are shown in the single channel
images. Colocalization of GFP-b-arrestin-2 and RFP-ERK2 is shown in the overlay
images (yellow; arrows). Each image depicts a representative confocal micro-
scopic image from one of three separate experiments.
Fig. 2. Effect of angiotensin II on the cellular distribution of RFP-ERK2 and
phospho-ERK1y2. HEK-293 cells were transiently transfected with plasmid
DNA encoding HA-AT1aR, Flag-b-arrestin-2, and RFP-ERK2. Serum-starved
cells were treated with vehicle (NS), PMA, or angiotensin II (Ang II) for 15 min,
fixed with paraformaldehyde, permeabilized, and stained with FITC-
conjugated monoclonal anti-phospho-ERK1y2 before examination by confo-
cal microscopy. The distribution RFP-ERK2 (red) and FITC-stained phospho-
ERK1y2 (green) are shown in the single channel images. Colocalization of
RFP-ERK2 and phospho-ERK1y2 is shown in the overlay images (yellow; ar-
rows). Each image depicts a representative confocal microscopic image from
one of three separate experiments.
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suggest that the binding of cRaf-1 to b-arrestin-2 facilitates the
assembly of a multiprotein complex on the b-arrestin that
contains each of the component kinases of the ERK cascade.
To determine the effect of cRaf-1 on the phosphorylation of
b-arrestin-bound ERK2, COS-7 cells expressing Flag-b-
arrestin-2 and GFP-ERK2 were cotransfected with increasing
amounts of the plasmid encoding myc-cRaf-1. As shown in Fig.
3C, increasing cRaf-1 expression resulted in a 2- to 3-fold
increase in the amount of GFP-ERK2 that coprecipitated with
Flag-b-arrestin-2. At the same time, the phosphorylation of
b-arrestin-associated GFP-ERK2 increased 30- to 35-fold, con-
sistent with cRaf-1 dependent phosphorylation of ERK2 in the
b-arrestin complex (upper immunoblot and lower left bar
graph). Because the activation of the ERK MAPK by the MAPK
kinase kinase cRaf-1 should require a MAPK kinase, such as
MEK1 (19), we used a dominant negative mutant of MEK1,
MEK1(K97A), to determine whether the effect of cRaf-1 ex-
pression on b-arrestin-bound GFP-ERK2 depended on endog-
enous MEK activity. As shown, the myc-cRaf-1-dependent phos-
phorylation of GFP-ERK2 was significantly reduced in the
presence of coexpressed MEK1(K97A) (upper immunoblot and
lower right bar graph). These data suggest that b-arrestins, in
addition to complexing with each of the component kinases of
the ERK cascade, may function as scaffolds that facilitate cRaf-1
and MEK-dependent activation of b-arrestin-bound ERK.
Fig. 4 depicts the effects of AT1aR stimulation on the binding
of myc-cRaf-1 and GFP-ERK2 to Flag-b-arrestin-2, and on the
recruitment of b-arrestin-2ycRaf-1yERK2 complexes to the
agonist-occupied AT1aR. As shown in Fig. 4A, angiotensin
stimulation of COS-7 cells transiently expressing HA-AT1aR,
Flag-b-arrestin-2, myc-cRaf-1, and GFP-ERK2 resulted in in-
creased association of Flag-b-arrestin-2 with both myc-cRaf-1
and GFP-ERK2, suggesting that the conformational changes
induced in b-arrestin-2 upon binding the receptor facilitates
complex assembly. The agonist effect was detectable within 2
min of stimulation and maximal by 5 min, consistent with the
time course of recruitment of GFP-b-arrestin-2 to agonist-
occupied AT1aR (12). As shown in Fig. 4B, angiotensin stimu-
lation increased the amount of Flag-b-arrestin-2, myc-cRaf-1,
and GFP-ERK2 present in HA-AT1aR immunoprecipitates
after covalent crosslinking with DSP. These data are consistent
with the findings obtained by confocal microscopy in HEK-293
cells, that angiotensin stimulation caused the assembly of
AT1aRyb-arrestinyERK complexes that were subsequently tar-
geted to endosomal vesicles.
Discussion
Fig. 5 depicts a model of b-arrestin-dependent ERK activation
that is consistent with our data. The binding of agonist to
heptahelical receptors results in the dissociation of heterotri-
meric G proteins into Ga and Gbg subunits, which go on to
regulate various effectors. One consequence of Gbg subunit
release is the recruitment of G protein-coupled receptor kinases
(e.g., GRK2 and GRK3) that phosphorylate the agonist-
occupied receptor and increase its affinity for binding to b-
DNA encoding GFP-ERK2 and increasing amounts of myc-cRaf-1, in the pres-
ence and absence of Flag-b-arrestin-2 and MEK(K97A) as indicated. The
amount of GFP-ERK2 and phospho-GFP-ERK2 present in Flag-b-arrestin-2
immunoprecipitates was determined by immunoblotting (Upper). Graphs
depict the amount of GFP-ERK2 and phospho-GFP-ERK2 present in Flag-b-
arrestin-2 immunoprecipitates (Left) and the effect of MEK(K97A) expression
on the amount of phospho-GFP-ERK2 present in Flag-b-arrestin-2 immuno-
precipitates (Right). Data are presented in arbitrary units where the amount
of GFP-ERK2 or phospho-GFP-ERK2 present in Flag-b-arrestin-2 immunopre-
cipitates in the absence of overexpressed myc-cRaf-1 is defined as 1. Data
shown represent the mean 6 SD from three separate experiments.
Fig. 3. Binding of myc-cRaf-1, MEK1 and activated GFP-ERK2 to wild-type
and mutant Flag-b-arrestin-2. (a) COS-7 cells were transiently transfected with
plasmid DNA encoding myc-cRaf-1, MEK1, GFP-ERK2, and Flag-b-arrestin-2 in
various combinations as indicated. GFP-ERK2, which undergoes agonist-
stimulated phosphorylation and nuclear translocation like the wild-type ki-
nase (10; not shown), was used in these studies to allow each overexpressed
protein to have a unique epitope tag. Anti-Flag immunoprecipitates were
probed for coprecipitated cRaf-1, MEK1, ERK2, and b-arrestin-2. Equivalent
expression of each construct was confirmed by immunoblotting an aliquot of
each whole cell lysate in parallel (not shown). Shown are representative
immunoblots from one of six separate experiments. (b) Bar graphs depict the
amount of myc-cRaf-1 (Left) and GFP-ERK2 (Right) present in Flag-b-arrestin-2
immunoprecipitates from cells coexpressing myc-cRaf-1 only, GFP-ERK2 only,
or both myc-cRaf-1 and GFP-ERK2. Data are presented in arbitrary units where
the amount of myc-cRaf-1 or GFP-ERK2 binding to Flag-b-arrestin-2 when
singly expressed is defined as 1. Data shown represent the mean 6 SD from
four separate experiments. (c) Cells were transiently transfected with plasmid
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arrestin (5). The component kinases of the ERK cascade, Raf-1,
MEK, and ERK, subsequently assemble using b-arrestin as a
scaffold and leading to activation of ERK. Endocytosis of these
receptoryb-arrestin complexes by clathrin-coated pits results in
the targeting of activated ERK to endosomal vesicles. The
complexes, once formed, appear to be relatively stable, because
they can be detected both by confocal microscopy and by
immunoprecipitation techniques.
Multiple mechanisms are used by heptahelical receptors to
regulate the activity of MAPK cascades (3, 4). These include
second messenger-dependent pathways, such as the protein
kinase A-dependent phosphorylation of the small G protein
Rap1 in hematopoetic cells (20, 21), the protein kinase C-
dependent activation of Raf isoforms (17), and the calcium- and
cell adhesion-dependent activation of the focal adhesion kinase
Pyk2 in neuronal cells (22, 23). In addition, many heptahelical
receptors stimulate the transactivation of classical receptor
tyrosine kinases, such as the epidermal growth factor (EGF) (24,
25) and platelet-derived growth factor (PDGF) receptors (26,
27). EGF receptor transactivation is the consequence of hepta-
helical receptor-mediated release of membrane-bound EGF-like
ligands, such as heparin-binding EGF, through the action of as
yet unidentified matrix metalloproteases (28). Signaling by
means of b-arrestin scaffolds represents another, mechanistically
distinct, means of MAPK regulation by heptahelical receptors.
The predominant mechanism used by any given heptahelical
receptor to activate the ERK cascade varies between cell types
and is apparently determined by the cellular context in which the
receptor is expressed. In some cases, endogenous heptahelical
receptors employ multiple mechanisms simultaneously (29).
Indeed, AT1aR have been shown to trigger transactivation of
both EGF (30) and PDGF receptors (31). Why should this
seeming redundancy exist? One exciting possibility is that the
consequences of ERK activation are determined to a significant
degree by the mechanism by which they are activated. ERK
substrates have been identified in the plasma membrane, cyto-
plasm, cytoskeleton, and nucleus. In addition to their role in
regulating the phosphorylation of nuclear transcription factors
(19), ERK1y2 have been reported to phosphorylate several
proteins involved in heptahelical receptor signaling, such as
b-arrestin-1 (32) and GRK2 (33, 34). Activation of the ERK
cascade by transactivated EGF receptors or b-arrestin scaffolds,
for example, may provide mechanisms for controlling both the
time course and spatial distribution of ERK activity, leading to
distinctly different consequences for the cell. Early evidence for
this is provided by the finding that wild-type PAR-2 receptors,
which cause b-arrestin-dependent activation of a cytosolic pool
of ERK1y2, do not mediate mitogenic responses in KNRK cells.
In contrast, mutant PAR-2 receptors that cannot bind b-arrestin,
but still activate ERK1y2 through a calcium-dependent pathway,
stimulate nuclear translocation of the ERK and provoke a
proliferative response (10).
Our appreciation of b-arrestins as multifunctional adapter
proteins is still evolving. In addition to their originally described
roles in uncoupling heptahelical receptors from their cognate G
proteins and in targeting receptors for endocytosis, b-arrestins
increasingly appear to be directly involved in heptahelical re-
ceptor signaling. Through their ability to recruit Src kinases
(6–8), and to act as scaffolds for the ERK (8, 10) and JNK (11)
MAPK cascades, the binding of b-arrestins serves to trigger a
second wave of signals emanating from the receptor. Thus,
b-arrestins, like heterotrimeric G proteins, link heptahelical
receptors to a defined subset of effector enzymes.
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Fig. 4. Effect of angiotensin II stimulation on the assembly of complexes containing HA-AT1aR, Flag-b-arrestin-2, myc-cRaf-1, and GFP-ERK2. (a) COS-7 cells were
transiently transfected with plasmid cDNA encoding HA-AT1aR, Flag-b-arrestin-2, myc-cRaf-1, and GFP-ERK2. Serum-starved cells were stimulated with angiotensin II
(Ang II) for the time indicated. The amount of myc-cRaf-1 and GFP-ERK2 present in Flag-b-arrestin-2 immunoprecipitates was determined by immunoblotting. (b)
Serum-starved cells were stimulated with angiotensin II (Ang II) for 5 min before covalent crosslinking of receptor-associated proteins with DSP. The amount of
myc-cRaf-1, GFP-ERK2, and Flag-b-arrestin-2 present in HA-AT1aR immunoprecipitates was determined by immunoblotting. Immunoblots shown are representative
of three to five separate experiments.
Fig. 5. Model of ERK activation and targeting by b-arrestin scaffolds. Agonist
(H) binding to heptahelical receptors results in dissociation of heterotrimeric
G proteins into Ga-GTP and Gbg subunits, which activate G protein effectors
(E). One consequence of Gbg subunit release is enhanced GRK-mediated
phosphorylation of the agonist-occupied receptor. b-Arrestins 1 (b-arr) bind
to both GRK-phosphorylated receptor and to the component kinases of the
ERK cascade, resulting in assembly of an ERK activation complex that is
targeted into endosomal vesicles.
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